Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPE OTCMKTS:ATRX NASDAQ:CMRA OTCMKTS:SPHS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.02$0.00▼$0.13$3K4.76694 shs24 shsATRXAdhera Therapeutics$0.00$0.00▼$0.02N/A4628 shsN/ACMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K1.286,565 shs100 shsSPHSSophiris Bio$0.00$0.00▼$0.05$4K1.94N/AN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+7.41%+7.41%+31.82%ATRXAdhera Therapeutics0.00%0.00%0.00%0.00%-98.75%CMRAComera Life Sciences0.00%0.00%0.00%+100.00%-99.10%SPHSSophiris Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/AATRXAdhera Therapeutics 0.00N/AN/AN/ACMRAComera Life Sciences 0.00N/AN/AN/ASPHSSophiris Bio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/ACMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞SPHSSophiris BioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/AATRXAdhera Therapeutics-$2.11MN/A0.00N/AN/AN/AN/AN/AN/ACMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/ASPHSSophiris BioN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%ATRXAdhera TherapeuticsN/ACMRAComera Life SciencesN/ASPHSSophiris BioN/AInsider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%ATRXAdhera Therapeutics28.20%CMRAComera Life Sciences8.90%SPHSSophiris Bio4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataATRXAdhera Therapeutics211.63 million8.35 millionNot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableSPHSSophiris Bio635.55 millionN/ANot OptionableATRX, SPHS, AMPE, and CMRA HeadlinesRecent News About These CompaniesWisr AI Systems Inc. Announces Closing of AmalgamationDecember 20, 2024 | newsfilecorp.comNBioinspired materials articles from across Nature PortfolioNovember 13, 2024 | nature.comNRyan Garcia: Biography, record, fights and moreDecember 3, 2023 | espn.comBest Louisiana High SchoolsOctober 13, 2023 | usnews.comSouth Portland High sends students home after morning lockdownOctober 9, 2023 | pressherald.comPBLTE - Belite Bio, IncJuly 20, 2023 | finance.yahoo.comTycho Brahe: Colorful life, accomplishments and bizarre deathJune 23, 2023 | space.comSBio-Reference LaboratoriesJune 12, 2023 | forbes.comCommunity News – Calling all Red Riots; South Portland H.S. Alumni Network launchedApril 15, 2023 | pressherald.comPUkraine conflict: Germany orders 10 PzH 2000 SPHs to replace those sent to KyivApril 2, 2023 | janes.comJSophiris Bio Inc. Registered Sh (BFF1.SG)March 20, 2023 | finance.yahoo.com18 ways you didn't know you could use bio-oil, plus the celebs who swear by itMarch 17, 2023 | womenshealthmag.comWSPHS Indoor Track Wins Girls Blue Division at GMC ChampionshipsJanuary 25, 2023 | msn.comSPHS Weekly Sports Recap: All Sports Notch Big WinsJanuary 17, 2023 | msn.comPennsylvania Gov.-elect Josh Shapiro biographyJanuary 14, 2023 | wgal.comWNarendra Modi Biography: Childhood, Family, Education, Political Life, Net Worth & Key FactsSeptember 17, 2022 | jagranjosh.comJWeapons newsSeptember 9, 2022 | janes.comJNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRX, SPHS, AMPE, and CMRA Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0029 0.00 (0.00%) As of 08/7/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Adhera Therapeutics OTCMKTS:ATRXAdhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Comera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 08/6/2025 10:58 AM EasternComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Sophiris Bio OTCMKTS:SPHSSophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
